The results of indirect comparison of Abecip and Mab are published

On April 9th, the results of the mesh meta-analysis compared the visual benefit and treatment burden between the Abbesicept intraocular injection solution and the ranibizumab "Treatment and Extension" (T & E) regimen. Published in "Therapeutic Progress". According to the analysis, compared with ranibizumab, neovascular (wet) age-related macular degeneration (wet AMD) patients treated with Abecipab had six fewer injections than ranibizumab within two years, but their vision was Benefit quite.

Dr. Patrick Bussfeld, Vice President and Head of Ophthalmology Medical Affairs at Bayer, said: "The results of this analysis help fill the gap in the clinical evidence for different anti-VEGF therapeutics to improve and maintain the benefits of vision and the burden of treatment. During the year, the visual acuity benefits of the two groups of patients treated with abesicept and ranibizumab were similar, but patients receiving abexicept received six fewer injections. "

Neovascular (wet) age-related macular degeneration (wet AMD) is a disease that affects the center of the retina. If there is no continuous and effective treatment, the disease will progress rapidly. Through the intravitreal anti-VEGF treatment using the treatment extension plan (T & E), after completing the initial fixed dose, the clinician can use an individualized treatment plan according to the patient's condition to gradually extend or shorten the injection interval.

Chen Youxin, director of the Department of Ophthalmology, Peking Union Medical College Hospital, said: "From the listing of Abecip in China in 2018, our clinical experience and clinical research results are very consistent. The same injection, using Abecip relative to monoclonal antibodies, The control effect of retinal vascular diseases such as nAMD and DME can last longer, then the number of injections of patients can be reduced accordingly. The sudden new coronary pneumonia epidemic makes our clinicians and patients more aware of the prolonged active treatment plan of Abecip The benefits of extended treatment intervals during the epidemic and fewer visits to the hospital not only reduce the burden on medical institutions and patient families, but also reduce the pressure on medical insurance costs, and can greatly reduce the risk of cross-infection between doctors and patients. "